p62/SQSTM1 in cancer: phenomena, mechanisms, and regulation in DNA damage repair.

Xiaojuan Yang, Xunjie Cao, Qing Zhu
Author Information
  1. Xiaojuan Yang: Liver Digital Transformation Research Laboratory, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, 610041, People's Republic of China.
  2. Xunjie Cao: Division of Abdominal Tumor Multimodality Treatment, Department of General Surgery, West China Hospital, Sichuan University, Cancer Center, Chengdu, 610041, China.
  3. Qing Zhu: Division of Abdominal Tumor Multimodality Treatment, Department of General Surgery, West China Hospital, Sichuan University, Cancer Center, Chengdu, 610041, China. newzhuqing1972@163.com. ORCID

Abstract

The multidomain protein cargo adaptor p62, also known as sequestosome 1, serves as a shuttling factor and adaptor for the degradation of substrates via the proteasome and autophagy pathways. Regarding its structure, p62 is composed of several functional domains, including the N-terminal Phox1 and Bem1p domains, a ZZ-type zinc finger domain, a LIM protein-binding domain that contains the tumor necrosis factor receptor-associated factor 6 (TRAF6) binding region, two nuclear localization signals (NLS 1/2), a nuclear export signal (NES), the LC3-interacting region (LIR), a Kelch-like ECH-associated protein 1 (KEAP1)-interacting region, and a ubiquitin-associated (UBA) domain. Recent studies have highlighted the critical role of p62 in the development and progression of various malignancies. Overexpression and/or impaired degradation of p62 are linked to the initiation and progression of numerous cancers. While p62 is primarily localized in the cytosol and often considered a cytoplasmic protein, most of the existing literature focuses on its cytoplasmic functions, leaving its nuclear roles less explored. However, an increasing body of research has uncovered p62's involvement in the cellular response to DNA damage. In this review, we summarize the current understanding of p62's molecular functions in malignancies, with particular emphasis on its role in DNA damage repair, highlighting the latest advances in this field.

Keywords

References

  1. Cell Cycle. 2010 Apr 1;9(7):1421-33 [PMID: 20305393]
  2. Cancer Sci. 2017 Jul;108(7):1405-1413 [PMID: 28498503]
  3. Science. 2001 Nov 23;294(5547):1713-6 [PMID: 11721054]
  4. Mol Cell. 2016 Jul 7;63(1):34-48 [PMID: 27345151]
  5. Cancer Biol Ther. 2013 Feb;14(2):100-7 [PMID: 23192274]
  6. Nucleic Acids Res. 2020 Dec 16;48(22):12689-12696 [PMID: 33166411]
  7. Science. 2019 Nov 15;366(6467):818-822 [PMID: 31727826]
  8. Thorac Cancer. 2020 Jan;11(1):130-139 [PMID: 31755241]
  9. Mol Cell. 2009 Feb 27;33(4):505-16 [PMID: 19250911]
  10. Mol Cell. 2013 Sep 12;51(5):618-31 [PMID: 24011591]
  11. Cold Spring Harb Perspect Biol. 2010 May;2(5):a000661 [PMID: 20452955]
  12. Free Radic Biol Med. 2013 Dec;65:102-116 [PMID: 23792273]
  13. Leukemia. 2016 Feb;30(2):390-8 [PMID: 26286116]
  14. Science. 2024 Aug 30;385(6712):eadj7446 [PMID: 39208097]
  15. Mol Cell Biol. 2002 Oct;22(20):6959-70 [PMID: 12242277]
  16. Int J Mol Sci. 2017 Mar 02;18(3): [PMID: 28257096]
  17. Nat Commun. 2021 Mar 29;12(1):1955 [PMID: 33782410]
  18. Cell Rep. 2022 Jul 19;40(3):111116 [PMID: 35858573]
  19. Proc Natl Acad Sci U S A. 2024 Oct 22;121(43):e2414377121 [PMID: 39418304]
  20. FEBS Lett. 1998 Sep 18;435(2-3):138-42 [PMID: 9762895]
  21. Oncogene. 2019 Dec;38(50):7473-7490 [PMID: 31444413]
  22. Int J Mol Sci. 2018 May 08;19(5): [PMID: 29738493]
  23. Nat Commun. 2021 Sep 1;12(1):5212 [PMID: 34471133]
  24. Oncogene. 2003 Apr 17;22(15):2322-33 [PMID: 12700667]
  25. Eur Rev Med Pharmacol Sci. 2016 May;20(10):1993-2003 [PMID: 27249597]
  26. J Biol Chem. 2011 Sep 9;286(36):31864-74 [PMID: 21715324]
  27. J Biomol Screen. 2013 Oct;18(9):1103-9 [PMID: 23741014]
  28. PLoS One. 2017 Mar 16;12(3):e0173712 [PMID: 28301876]
  29. Am J Pathol. 2015 Sep;185(9):2523-33 [PMID: 26162509]
  30. Cell Death Dis. 2016 Mar 31;7:e2163 [PMID: 27031960]
  31. Front Oncol. 2015 Mar 30;5:70 [PMID: 25870850]
  32. Oncotarget. 2016 Jun 28;7(26):39241-39255 [PMID: 27250034]
  33. J Biol Chem. 2010 Jan 15;285(3):2077-89 [PMID: 19903815]
  34. PLoS One. 2013 Sep 24;8(9):e74398 [PMID: 24086340]
  35. Front Oncol. 2021 Apr 15;11:638701 [PMID: 33937040]
  36. Nat Commun. 2019 Dec 19;10(1):5792 [PMID: 31857589]
  37. FEBS J. 2015 Dec;282(24):4672-8 [PMID: 26432171]
  38. Nat Commun. 2016 Jun 27;7:12030 [PMID: 27345495]
  39. Redox Biol. 2020 Jan;29:101392 [PMID: 31926620]
  40. Cell Cycle. 2009 Jul 1;8(13):1986-90 [PMID: 19502794]
  41. Cancer Cell. 2008 Apr;13(4):343-54 [PMID: 18394557]
  42. Cell. 2016 Oct 20;167(3):606-609 [PMID: 27768885]
  43. Mol Cell Biochem. 2014 Jan;385(1-2):95-102 [PMID: 24065390]
  44. J Biol Chem. 2010 Feb 19;285(8):5941-53 [PMID: 20018885]
  45. Int J Mol Sci. 2021 Sep 28;22(19): [PMID: 34638836]
  46. J Biol Chem. 2003 Sep 5;278(36):34568-81 [PMID: 12813044]
  47. Genes Dev. 2007 Jun 1;21(11):1367-81 [PMID: 17510285]
  48. Cancer Med. 2023 Jan;12(1):459-471 [PMID: 35676831]
  49. Cell. 2009 Jun 12;137(6):1001-4 [PMID: 19524504]
  50. J Cell Sci. 2017 Nov 15;130(22):3839-3850 [PMID: 29021346]
  51. Proc Natl Acad Sci U S A. 2021 Aug 17;118(33): [PMID: 34385323]
  52. Oncotarget. 2016 Jun 28;7(26):39544-39555 [PMID: 27250032]
  53. J Hepatobiliary Pancreat Sci. 2016 Aug;23(8):467-71 [PMID: 27246794]
  54. Cancer Cell. 2016 Jun 13;29(6):935-948 [PMID: 27211490]
  55. DNA Repair (Amst). 2012 Feb 1;11(2):192-200 [PMID: 22051193]
  56. Exp Mol Pathol. 2014 Apr;96(2):149-54 [PMID: 24369267]
  57. Eur J Med Chem. 2020 May 1;193:112231 [PMID: 32193054]
  58. J Invest Dermatol. 2014 May;134(5):1476-1478 [PMID: 24270664]
  59. PLoS Pathog. 2019 Apr 24;15(4):e1007541 [PMID: 31017975]
  60. Autophagy. 2017 Jan 2;13(1):212-213 [PMID: 27791533]
  61. Onco Targets Ther. 2013 Jul 19;6:883-8 [PMID: 23888115]
  62. EMBO Rep. 2010 Mar;11(3):226-32 [PMID: 20154642]
  63. Cancer Cell. 2007 Jul;12(1):9-22 [PMID: 17613433]
  64. Turk J Biol. 2021 Jun 23;45(3):235-252 [PMID: 34377049]
  65. Biochem Biophys Res Commun. 2014 Mar 28;446(1):309-15 [PMID: 24582747]
  66. Gut. 2021 Mar;70(3):606-617 [PMID: 32855305]
  67. Nature. 2009 Oct 22;461(7267):1071-8 [PMID: 19847258]
  68. Cell Cycle. 2012 Jan 1;11(1):170-6 [PMID: 22185757]
  69. Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):773-8 [PMID: 25568088]
  70. PLoS One. 2014 Mar 05;9(3):e90171 [PMID: 24599075]
  71. Cell Death Dis. 2021 Apr 14;12(4):405 [PMID: 33854041]
  72. EMBO J. 2000 Apr 3;19(7):1576-86 [PMID: 10747026]
  73. Cancer Res. 2009 Oct 15;69(20):7978-85 [PMID: 19808958]
  74. Science. 2024 Aug 30;385(6712):eadj8691 [PMID: 39208110]
  75. J Cell Biol. 2011 Apr 18;193(2):275-84 [PMID: 21482715]
  76. FEBS J. 2019 Jan;286(1):8-23 [PMID: 30499183]
  77. Histopathology. 2013 Jan;62(2):275-86 [PMID: 23134379]
  78. Mol Cell. 2013 Aug 8;51(3):283-96 [PMID: 23911927]
  79. J Biol Chem. 2011 Jun 24;286(25):22426-40 [PMID: 21536669]
  80. J Biol Chem. 2007 Aug 17;282(33):24131-45 [PMID: 17580304]
  81. Cancer Sci. 2012 Apr;103(4):760-6 [PMID: 22320446]
  82. Curr Cancer Drug Targets. 2019;19(6):468-478 [PMID: 30332964]
  83. Am J Clin Pathol. 2010 Sep;134(3):457-65 [PMID: 20716803]
  84. J Biol Chem. 2003 Sep 26;278(39):36989-92 [PMID: 12912994]
  85. Eur J Cancer. 2011 Jul;47(10):1585-94 [PMID: 21371883]
  86. Mol Cell. 2003 Jul;12(1):39-50 [PMID: 12887891]
  87. Mol Cell Biol. 2005 May;25(10):4010-22 [PMID: 15870274]
  88. Am J Cancer Res. 2012;2(4):397-413 [PMID: 22860231]
  89. J Biol Chem. 2005 Oct 21;280(42):35625-9 [PMID: 16079148]
  90. DNA Cell Biol. 2013 May;32(5):220-7 [PMID: 23530606]
  91. Cell. 2019 Feb 21;176(5):1054-1067.e12 [PMID: 30773316]
  92. Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2974-80 [PMID: 23023376]
  93. BMC Cancer. 2013 Mar 27;13:161 [PMID: 23537217]
  94. Nat Cell Biol. 2016 Dec 23;19(1):1-9 [PMID: 28008184]
  95. Nature. 2006 May 25;441(7092):431-6 [PMID: 16724054]
  96. Mol Cell Biol. 2010 Jul;30(13):3275-85 [PMID: 20421418]
  97. Nat Commun. 2017 Jul 24;8(1):102 [PMID: 28740232]
  98. Cell. 2009 Jun 12;137(6):1062-75 [PMID: 19524509]
  99. J Biol Chem. 2010 Jul 16;285(29):22576-91 [PMID: 20452972]
  100. J Biol Chem. 2008 Aug 15;283(33):22847-57 [PMID: 18524774]
  101. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7490-E7499 [PMID: 27791183]
  102. Mol Cell Biol. 2004 Sep;24(18):8055-68 [PMID: 15340068]
  103. Front Endocrinol (Lausanne). 2018 Jun 29;9:344 [PMID: 30008697]
  104. Mol Cell Biol. 2014 Apr;34(8):1380-8 [PMID: 24469398]
  105. Elife. 2015 Sep 28;4:e08941 [PMID: 26413874]
  106. Urol Oncol. 2014 Jan;32(1):39.e11-8 [PMID: 23787295]
  107. Autophagy. 2016 Oct 2;12(10):1917-1930 [PMID: 27391408]
  108. Autophagy. 2013 Oct;9(10):1591-603 [PMID: 23989536]
  109. Mol Cell Biol. 1998 May;18(5):3069-80 [PMID: 9566925]
  110. Anticancer Res. 2016 Jan;36(1):129-36 [PMID: 26722036]
  111. Essays Biochem. 2017 Dec 12;61(6):609-624 [PMID: 29233872]
  112. EMBO J. 1999 Jun 1;18(11):3044-53 [PMID: 10356400]
  113. J Biol Chem. 2000 May 26;275(21):16023-9 [PMID: 10821856]
  114. Science. 1999 Sep 3;285(5433):1565-9 [PMID: 10477520]
  115. Cancer Cell. 2013 Dec 9;24(6):738-50 [PMID: 24332042]
  116. Age (Dordr). 2014 Jun;36(3):9626 [PMID: 24557832]
  117. Exp Cell Res. 2015 Jul 1;335(1):68-81 [PMID: 25936772]
  118. Endocr Relat Cancer. 2007 Mar;14(1):73-80 [PMID: 17395976]
  119. Histopathology. 2006 Jan;48(2):157-61 [PMID: 16405664]
  120. Cell Rep. 2015 Aug 25;12(8):1339-52 [PMID: 26279575]
  121. Trends Endocrinol Metab. 2023 Aug;34(8):474-488 [PMID: 37349161]
  122. Trends Biochem Sci. 2009 Apr;34(4):176-88 [PMID: 19321346]
  123. Oncogene. 2018 Jun;37(24):3260-3274 [PMID: 29551772]
  124. Nat Rev Mol Cell Biol. 2019 Nov;20(11):698-714 [PMID: 31263220]
  125. J Bone Oncol. 2016 Feb 03;5(1):30-7 [PMID: 26998424]
  126. Hippocampus. 2009 Apr;19(4):392-406 [PMID: 19004011]

Grants

  1. 2025ZNSFSC1901/Sichuan Provincial Science and Technology Support Program

MeSH Term

Humans
Neoplasms
Sequestosome-1 Protein
DNA Damage
DNA Repair
Animals

Chemicals

Sequestosome-1 Protein
SQSTM1 protein, human

Word Cloud

Created with Highcharts 10.0.0p62proteinfactordomainregionnuclearDNAdamageadaptor1degradationdomainsroleprogressionmalignanciescytoplasmicfunctionsp62'srepairmultidomaincargoalsoknownsequestosomeservesshuttlingsubstratesviaproteasomeautophagypathwaysRegardingstructurecomposedseveralfunctionalincludingN-terminalPhox1Bem1pZZ-typezincfingerLIMprotein-bindingcontainstumornecrosisreceptor-associated6TRAF6bindingtwolocalizationsignalsNLS1/2exportsignalNESLC3-interactingLIRKelch-likeECH-associatedKEAP1-interactingubiquitin-associatedUBARecentstudieshighlightedcriticaldevelopmentvariousOverexpressionand/orimpairedlinkedinitiationnumerouscancersprimarilylocalizedcytosoloftenconsideredexistingliteraturefocusesleavingroleslessexploredHoweverincreasingbodyresearchuncoveredinvolvementcellularresponsereviewsummarizecurrentunderstandingmolecularparticularemphasishighlightinglatestadvancesfieldp62/SQSTM1cancer:phenomenamechanismsregulationDDRModularstructuresP62/SQSTM1Tumorigenesis

Similar Articles

Cited By

No available data.